Commerce Bank continued to hold its stake in Impax Laboratories, Inc. (NASDAQ:IPXL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,460 shares of the specialty pharmaceutical company’s stock at the close of the second quarter. Commerce Bank’s holdings in Impax Laboratories were worth $184,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Impax Laboratories by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock valued at $79,080,000 after purchasing an additional 276,765 shares during the period. North Tide Capital LLC increased its holdings in shares of Impax Laboratories by 50.0% in the first quarter. North Tide Capital LLC now owns 3,000,000 shares of the specialty pharmaceutical company’s stock valued at $37,950,000 after purchasing an additional 1,000,000 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Impax Laboratories by 47.2% in the first quarter. Dimensional Fund Advisors LP now owns 2,637,077 shares of the specialty pharmaceutical company’s stock valued at $33,359,000 after purchasing an additional 845,375 shares during the period. Frontier Capital Management Co. LLC increased its holdings in shares of Impax Laboratories by 43.2% in the second quarter. Frontier Capital Management Co. LLC now owns 1,585,828 shares of the specialty pharmaceutical company’s stock valued at $25,532,000 after purchasing an additional 478,168 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of Impax Laboratories by 88.4% in the first quarter. Point72 Asset Management L.P. now owns 1,095,600 shares of the specialty pharmaceutical company’s stock valued at $13,859,000 after purchasing an additional 514,200 shares during the period. 86.26% of the stock is currently owned by institutional investors and hedge funds.

Shares of Impax Laboratories, Inc. (NASDAQ IPXL) opened at 22.15 on Thursday. The firm’s market capitalization is $1.59 billion. The company’s 50-day moving average price is $18.88 and its 200 day moving average price is $15.26. Impax Laboratories, Inc. has a 12-month low of $7.75 and a 12-month high of $27.29.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.04. The firm had revenue of $202.08 million during the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The firm’s revenue was up 17.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.21 EPS. On average, equities research analysts forecast that Impax Laboratories, Inc. will post $0.70 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Impax Laboratories, Inc. (IPXL) Holdings Maintained by Commerce Bank” was published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/impax-laboratories-inc-ipxl-holdings-maintained-by-commerce-bank.html.

A number of research analysts have recently weighed in on IPXL shares. Deutsche Bank AG set a $21.00 price objective on Impax Laboratories and gave the company a “buy” rating in a report on Monday, July 17th. BidaskClub raised Impax Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. Zacks Investment Research raised Impax Laboratories from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Tuesday, July 11th. Cantor Fitzgerald set a $20.00 price objective on Impax Laboratories and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $16.00 price objective on shares of Impax Laboratories in a report on Friday, June 23rd. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $18.16.

Impax Laboratories Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.